Nova Bay Pharmaceuticals, Inc. NBY
We take great care to ensure that the data presented and summarized in this overview for NovaBay Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NBY
View allLatest Institutional Activity in NBY
Top Purchases
Top Sells
About NBY
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Insider Transactions at NBY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 11
2023
|
Yongxiang Zheng Director |
BUY
Exercise of conversion of derivative security
|
Direct |
858
+50.0%
|
-
|
|
May 11
2023
|
Julie Garlikov Director |
BUY
Exercise of conversion of derivative security
|
Direct |
858
+50.0%
|
-
|
|
May 11
2023
|
Swan Sit Director |
BUY
Exercise of conversion of derivative security
|
Direct |
858
+33.33%
|
-
|
|
May 11
2023
|
Mijia Wu Director |
BUY
Exercise of conversion of derivative security
|
Direct |
858
+33.33%
|
-
|
|
May 11
2023
|
Yenyou Zheng Director |
BUY
Exercise of conversion of derivative security
|
Direct |
858
+33.33%
|
-
|
|
May 11
2023
|
Paul E. Freiman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
858
+33.33%
|
-
|
|
Dec 06
2022
|
Jeffrey Kunin President, DERMAdoctor, LLC |
SELL
Open market or private sale
|
Indirect |
1
-100.0%
|
$1
$1.81 P/Share
|
|
Dec 06
2022
|
Audrey Kunin Chief Product Officer |
SELL
Open market or private sale
|
Indirect |
1
-100.0%
|
$1
$1.81 P/Share
|
|
Nov 21
2022
|
Jeffrey Kunin President, DERMAdoctor, LLC |
SELL
Open market or private sale
|
Indirect |
5,960
-100.0%
|
$11,920
$2.1 P/Share
|
|
Nov 21
2022
|
Audrey Kunin Chief Product Officer |
SELL
Open market or private sale
|
Indirect |
5,960
-100.0%
|
$11,920
$2.1 P/Share
|
|
Sep 14
2022
|
Jeffrey Kunin President, DERMAdoctor, LLC |
SELL
Open market or private sale
|
Indirect |
291,368
-58.27%
|
$0
$0.16 P/Share
|
|
Sep 14
2022
|
Audrey Kunin Chief Product Officer |
SELL
Open market or private sale
|
Indirect |
291,368
-58.27%
|
$0
$0.16 P/Share
|
|
Sep 14
2022
|
Justin Hall CEO, GC and Director |
BUY
Open market or private purchase
|
Direct |
10,000
+10.73%
|
$0
$0.15 P/Share
|
|
May 21
2022
|
Swan Sit Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+50.0%
|
-
|
|
May 21
2022
|
Paul E. Freiman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+50.0%
|
-
|
|
May 21
2022
|
Yenyou Zheng Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+50.0%
|
-
|
|
May 21
2022
|
Mijia Wu Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+50.0%
|
-
|
|
Dec 06
2021
|
Justin Hall CEO, GC and Director |
BUY
Open market or private purchase
|
Direct |
69,767
+48.81%
|
$0
$0.43 P/Share
|
|
Dec 06
2021
|
Andrew D. Jones CFO |
BUY
Open market or private purchase
|
Direct |
36,765
+22.39%
|
$0
$0.44 P/Share
|
|
Dec 03
2021
|
Audrey Kunin Chief Product Officer |
BUY
Open market or private purchase
|
Indirect |
101,650
+16.9%
|
$0
$0.46 P/Share
|